Previously located in New Jersey, Signum Biosciences is a private biotechnology company structured around developing small-molecule therapeutics derived from the firm's phosphatase platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic agents for Alzheimer's, Parkinson's, and other neurodegenerative diseases. Signum's phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics. The company also provides Cognion, a coffee extract that contains high levels of SIG1012 for cognitive performance and mental acuity, cardio-protection, anti-diabetic, anti-cancer, and sports performance.
